Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the issues in human health caused by biofilms in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for postoperative wound; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
| Market Capitalization | $106.3376 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.11 |
| EBITDA | -13,897.487 |
| Profit Margin | -0.896 |
| Operating Margin TTM | -0.8726 |
| Return on Assets TTM | -0.5782 |
| Return on Equity TTM | -2.0626 |
| Revenue TTM | 16,414.373 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2016-12-31 | 88.35 | 160.73 | -72.38 | 3,607 |
| 2017-12-31 | 483.24 | 123.57 | 359.67 | 6,532 |
| 2018-12-31 | 2,844.5 | 370.49 | 2,474.01 | 16,659.016 |
| 2019-12-31 | 4,060.8 | 550.48 | 3,510.32 | 16,046.807 |
| 2020-12-31 | 3,440.975 | 524.134 | 2,916.841 | 15,448.142 |
| 2021-12-31 | 8,947.591 | 2,007.469 | 6,940.122 | 16,547.664 |
| 2022-12-31 | 11,712.722 | 2,563.024 | 9,149.698 | 22,742.118 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2016-12-31 | 793.85 | 1,597.17 | 249.59 | 0 | 11,052.45 | |
| 2017-12-31 | 1,334.93 | 7,492.17 | 823.01 | 407.62 | 17,605.95 | |
| 2018-12-31 | 30,600 | 33,853 | 3,157 | 7,069.42 | 87,900 | |
| 2019-12-31 | 16,910.605 | 22,699.73 | 3,336.284 | 196.442 | 90,693.59 | |
| 2020-12-31 | 8,100.416 | 23,638.874 | 4,725.88 | 170.946 | 101,281.467 | |
| 2021-12-31 | 7,000.869 | 13,716.945 | 2,950.45 | 166.235 | 102,921.007 | |
| 2022-12-31 | 5,073.625 | 12,459.656 | 4,423.931 | 257.912 | 113,526.533 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2016-12-31 | -2,523 | -12,252.913 | -203.74 | |||
| 2017-12-31 | -2,443 | -12,252.913 | 4,613.335 | |||
| 2018-12-31 | -13,747.504 | -12,252.913 | 4,613.335 | 10,292.75193 | ||
| 2019-12-31 | -16,452.972 | -12,331.556 | 9,699.503 | 7,211.102 | 16,910.605 | -141.596 |
| 2020-12-31 | -11,303.263 | -11,906.644 | -1,571.203 | 16,910.605 | 15,339.402 | |
| 2021-12-31 | -9,349.639 | -8,264.354 | -7,971.404 | 15,339.402 | 7,367.998 | |
| 2022-12-31 | -11,834.17 | -10,937.069 | -2,256.584 | 7,367.998 | 5,111.414 |